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PMD31
DECISION-ANALYTIC MODELING IN
PARKINSON’S DISEASE
Siebert U1, Bornschein B2,Walbert T3, Dodel R3
1Harvard University, Boston, MA, USA; 2University of Munich,
Munich, Germany; 3University of Bonn, Bonn, Germany
OBJECTIVES: To give a systematic overview on pub-
lished decision-analytic studies and methodological
approaches in the evaluation of therapies in Parkinson’s
disease (PD) and derive generic recommendations for
future PD decision models. METHODS: A systematic lit-
erature review was performed to identify studies that
evaluated interventions for PD using mathematical
models. Using a standardized assessment form, informa-
tion on methodological framework, results, limitations
and conclusions were extracted from publications and
reported in systematic evidence tables. The evidence on
strengths and limitations was summarized in recommen-
dations for further PD modeling. RESULTS: We identi-
ﬁed 8 studies [1–8] that used mathematical models to
evaluate the effect of different pharmaceutical and surgi-
cal treatment options in PD in different settings and coun-
tries. Modeling approaches comprised mathematical
equations as well as decision-trees and Markov models
with a time horizon ranging from 5 years to lifetime. All
models based progression on the evolution of clinical sur-
rogate endpoints and included economic consequences.
No model is currently available that encompasses both
the underlying biologic disease progression and the spec-
trum of all relevant complications, and in addition, links
them to patient preferences as well as to economic out-
comes. CONCLUSIONS: A generic and ﬂexible decision
model for PD, that can be applied to different treatment
strategies should consider the entire spectrum of clinically
relevant outcomes and complications during an ade-
quately long time horizon and should be externally vali-
dated. Models for economic evaluations adoping a
societal perspective should include patient preferences
and all relevant economic consequences including those
of adverse events. Evaluating early diagnosis in combina-
tion with neuroprotective therapies requires the use of
health states that represent the natural history of the
disease in untreated patients such as Hoehn & Yahr off
stages or histologically deﬁned health states.
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ENSURING A STANDARD USER INTERFACE FOR
MODELS: MODEL-IT
Caro JJ, Magno LL
Caro Research Institute, Concord, MA, USA
Cost-containment pressures worldwide are increasing the
demand on drug developers to demonstrate the value of
products in order to obtain reimbursement. To meet this
demand, developers are turning to economic models.
While models are informative tools, they can be expen-
sive to produce, their complexity makes them difﬁcult to
understand and the lack of standardized formatting
makes them hard to navigate. OBJECTIVE: To develop
a low cost tool that allows model results to be viewed in
a standard format and to increase interdisciplinary access
models in order to support wider use in the development
and marketing of new pharmaceuticals. METHODS: An
electronic viewer (MODEL-IT) was developed as a “con-
tainer” to display and run analyses of disease models.
Building on the widespread familiarity of Windows©, the
tool was programmed to work as a stand-alone applica-
tion in a Win2000, WinXT, or WinNT environment.
Screens were developed to display inputs and outcomes
pertinent to the model being analyzed, while maintaining
a consistent format. Incorporation of point and click tech-
nology was used to simplify model functions by pro-
gramming buttons to carry out speciﬁc tasks. RESULTS:
The MODEL-IT tool breaks input parameters into spe-
ciﬁc categories including drug efﬁcacy, population 
characteristics and country-speciﬁc costs. All ﬁelds are
editable. Outcomes are model-speciﬁc and include costs,
survival and cost-effectiveness. Model edits can be saved
for later use, printed and exported to other programs. To
allow users access to detailed model information, the
technical manual can be accessed through a button
control. CONCLUSIONS: Current trends in the in-
creased use of pharmacoeconomic analysis will demand
standardization of models to streamline efﬁciency and
transfer expertise to multidisciplinary users. Standardized
user interfaces will become increasingly important in
meeting these needs.
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THE USE OF A SEMI-MARKOV PROCESS MODEL
IN COST-EFFECTIVENESS MODELING: THE
CASE OF ANTI-EPILEPTIC DRUGS
Hawkins NS, Epstein D, Sculpher M
University of York,York, North Yorkshire, United Kingdom
OBJECTIVE: Markov models are often used as part of
cost-effectiveness analysis to extrapolate from short-term
experimental evidence. Most Markov models used in 
economic evaluation typically assume ﬁxed transition
probabilities with respect to time. This is because imple-
mentation of time-dependant probabilities for all states is
difﬁcult in widely used modeling software. This is a lim-
iting assumption when transitions are clearly time depen-
dent. In such circumstances, semi-Markov processes, with
time-dependent probabilities, may be necessary to
provide reliable estimates of cost-effectiveness. ME-
THODS: The implementation of a semi-Markov process
will be illustrated using a recent analysis of anti-epileptic
drug sequences for the National Institute for Clinical
Excellence. In this case study, the probability of treatment
failure was dependant on the time spent on the current
treatment. Although such models can be implemented in
Excel or other modeling applications, the large number
of states required makes this cumbersome. As an alter-
native, the model was realized using “R”, a statistical 
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programming language, using a 3-dimensional transition
matrix, where the third dimension represents time spent
in the current state. The ability of R to manipulate n-
dimensional numeric arrays allowed the complex model
to be easily implemented. RESULTS: The use of a semi-
Markov process to model cost-effectiveness in epilepsy
allowed the reported natural history of the condition to
be accurately reﬂected. This was achieved efﬁciently and
transparently using the R statistical programming lan-
guage. Furthermore, the alternative (and commonly 
used) assumption of ﬁxed transition probabilities with
respect to time generated important differences in cost-
effectiveness results compared to the semi-Markov
process. CONCLUSIONS: Semi-Markov process models
may be useful in modeling a wide range of treatment
processes. By adding further dimensions to the transition
matrix, the transition probabilities could be made depen-
dant on other aspects of patients’ history providing a
useful alternative to discrete event simulation, where
increased speed of execution will aid probabilistic mod-
eling.
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ANALYTIC CHOICES IN ECONOMIC MODELS
OF TREATMENTS FOR RHEUMATOID
ARTHRITIS: WHAT MAKES A DIFFERENCE?
Barbieri M1, Drummond MF1,Wong J2
1Innovus Research UK Ltd, High Wycombe, United Kingdom;
2New England Medical Center, Boston, MA, USA
OBJECTIVES: To compare the analytic judgements, data
and assumptions of different models used in the economic
evaluation of inﬂiximab, one of a new class of drugs for
rheumatoid arthritis (RA). The purpose was to under-
stand why different models give such varying results.
METHODS: A detailed assessment was made of three
models, one submitted (in a reimbursement dossier) by
the manufacturer, one produced by an independent aca-
demic group and one published in the literature. Factors
considered included the key data inputs, assumptions
about the sequencing of treatments for RA, the estima-
tion of cost offsets and the modelling of the maintenance
of treatment effect for patients continuing or discontinu-
ing inﬂiximab. RESULTS: Two of the models, although
embodying different methodological approaches, gave
fairly similar results (approximately £30,000–£40,000
cost per additional quality-adjusted life-year gained). The
third model, by the independent academic group, gave
much higher estimates, around £100,000 per QALY. The
differences were mainly because of the assumptions about
the positioning of inﬂiximab in the treatment sequence
and assumptions about the long-term effect of therapy.
CONCLUSIONS: Economic models of treatments for
rheumatoid arthritis incorporate several key analytic
judgements, which can have major impacts on cost-effec-
tiveness. Two of the three models examined gave similar
results, which suggests that consensus can be reached on
several of the main methodological issues.
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A METHODOLOGICAL APPROACH TO ASSESS
COST DUE TO DYING IN THE CONTEXT OF
DECISION ANALYTIC MODELLING
Aidelsburger P1,Wasem J2
1University of Greifswald, Greifswald, Germany; 2University
Duisburg-Essen, Essen, Germany
OBJECTIVES: Decision analytic models relate health
outcomes in a speciﬁc health state with the costs arisen
in this health state. In most of the decision analytic
models we will ﬁnd the option that people will die either
due to a speciﬁc disease or due to other unspeciﬁed
causes. Treatment costs in the last two years before dying
are exceptionally high. Applying the health state costs to
a patient who is dying will underestimate the true costs.
Additional costs should be applied to correct for this
potential bias. This will present a methodological and
pragmatical approach to estimate costs due to dying 
of a disease speciﬁc cause and unspeciﬁed causes.
METHODS: Age-speciﬁc and non age-speciﬁc costs were
calculated. Dying of unspeciﬁed causes revealed to the
most common causes for dying reﬂecting a background
mortality. To assess the disease speciﬁc costs of dying—
in our case for hepatitis C virus associated diseases; rele-
vant causes of dying have been identiﬁed. Principle of all
cost calculations was the combination of length of termi-
nal hospital stay multiplied by per diem costs. RESULTS:
Over the age of 15 years costs of dying are similar for
disease-speciﬁc causes and unspeciﬁed causes with a range
between €2.133 and €3.701. In the age group between 0
and 4 years costs for unspeciﬁed causes are about €7.645,
in the age group between 5 and 14 years costs are €8.011.
Hepatitis C Virus associated costs for both age groups are
€19.987, respectively €13.018. CONCLUSIONS: The
described pragmatical approach just considers additional
costs in consequence of the last inpatient treatment before
death. Therefore costs are still underestimated. Main
advantage of the described approach will be the applica-
bility to different decision analytic models.
METHODOLOGICAL ISSUES—Other Studies
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ARE ISPOR SHORT COURSES A COST-
EFFECTIVE WAY OF EDUCATING
PARTICIPANTS AND ENHANCING MEETING
ATTENDANCE?
Basskin LE1,Augustyniak L2
1Trinka Medical Publications, Cooper City, FL, USA; 2ISPOR,
Lawrenceville, NJ, USA
OBJECTIVES: The purpose of this study was to deter-
mine whether short courses offered by ISPOR at its
Annual Meeting are a cost-effective means of education
and enhancing meeting attendance, or if the type, com-
plexity, number, or duration of the courses should be
changed. METHOD: Four different survey techniques
